The Leukodystrophy Gene Panel by NGS analyzes genes responsible for disorders affecting the white matter of the brain due to abnormal myelin development or degeneration. Using an EDTA blood sample, this test identifies inherited mutations linked to progressive motor decline, developmental delays, and neurological dysfunction. Metropolis Healthcare utilizes advanced next-generation sequencing for precise and comprehensive genetic profiling. The results support early diagnosis, targeted management, and family counseling for suspected leukodystrophies
Price:
Rs. 20,000.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes:G0217
Frequently Asked Questions (FAQ's):
What does the Leukodystrophy Gene Panel include at Metropolis Healthcare?
It evaluates a wide range of genes involved in myelin formation and maintenance using high-precision next-generation sequencing.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare extracts DNA from an EDTA blood sample and sequences targeted genes to identify variants associated with leukodystrophies.
Who should consider taking this test at Metropolis Healthcare?
Patients with developmental delays, progressive neurological decline, or MRI findings of white matter abnormalities may benefit from this panel.
What sample is required for this test at Metropolis Healthcare?
A standard EDTA blood sample is used to obtain high-quality DNA for sequencing.
How long does Metropolis Healthcare take to provide results?
Results are delivered within a typical genetic testing timeframe after thorough sequencing and expert analysis.
Why choose Metropolis Healthcare for leukodystrophy testing?
Metropolis Healthcare offers broad gene coverage, accurate variant detection, and clinically meaningful interpretation.
Does Metropolis Healthcare provide post-test guidance?
Yes, comprehensive genetic insights accompany the report to help clinicians plan appropriate treatment and family counseling.
Is this test suitable for children at Metropolis Healthcare?
Yes, the panel is appropriate for infants, children, and adults with suspected leukodystrophy